CDC’s role in tracking variants

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Sept. 8, 2021
  
  In the United States, CDC uses genomic surveillance to track emerging SARS-CoV-2 variants that cause COVID-19. CDC established multiple pipelines to connect genomic sequence data from CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible databases maintained by the National Center for Biotechnology Information (NCBI) and the Global Initiative on Sharing Avian Influenza Data.
  
  As part of the CDC National SARS-CoV-2 Strain Surveillance (NS3) System, public health laboratories ship deidentified specimens to CDC to provide a representative set of viruses for sequencing. There are four main stages in the process of generating SARS-CoV-2 genetic sequence data from these specimens and making it available in public repositories.
  
  
• Subjects:
  Betacoronavirus Coronavirus Infections COVID-19 Epidemiological Monitoring Genetic Variation Molecular Epidemiology Pneumonia, Viral Population Surveillance SARS-CoV-2
• Document Type:
  Webpage
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:b0a0e4261207ed16219ba152b6db10cf7180d04c2fbdb7da855a9772b23cf1f3
• Download URL:
  https://stacks.cdc.gov/view/cdc/115181/cdc_115181_DS1.pdf
• File Type:
  [PDF - 642.50 KB ]